Chemotherapy - Alkylating Agents
Chemotherapy - Alkylating Agents
Chemotherapy - Alkylating Agents
Learning Objectives
Explain mechanisms of alkylating agents,
discriminating key differences between bifunctional
and monofunctional agents in creating inter-strand
cross-links in cancer cell DNA.
Understand the likely mechanisms of action of
platinum compounds and the association of antineoplastic platinum compounds and kidney damage.
Gain familiarity with common side effects associated
with anti-neoplastic drug administration, including
neutropenia, anemia, thrombocytopenia, hair loss, and
gonadal dysfunction
Bifunctional vs monofunctional
Alkylating Agents
Bifunctional (dialkylating)- can react with
2 different residues resulting in cross
linkage (antineoplastic drugs)
Monofunctional (monoalkylating)- can
react with only one N7 of guanine so do not
prevent separation of DNA strands of helix
but prevent DNA processing enzymes from
accessing DNA (mutagens and carcinogens)
immonium ion
CH2
CH2
N:
R
CH2
CH2
alkylating agent
CH2
CH2
CH2
Cl
Cl
+
N
CH2
CH
N
guanine (or other
intracellular nucleophile)
CH2
N
CH2
carbonium ion
CH2
Cl
CH2
N:
CH2
R
CH2
CH
CH2
Cl
adducted guanine
guanine
+
CH2
guanine
CH2
CH2
CH2
CH2
guanine
CH2 CH2 N
R
immonium ion
CH2
carbonium ion
bifunctional
alkylating agent
cross-link
DNA replication
R
N
bifunctional
alkylating agent
cross-link
CH2
CH2
Cl
CH2
CH2
Cl
CH3
mechlorethamine
(nitrogen mustard)
HOOC
HOOC CH CH2
chlorambucil
NH2
melphalan (L-phenylalanine
mustard; (L-PAM)
N
O
NH
O
P
O
cyclophosphamide
P
O
CH2
NH
CH2
CH2
ifosfamide
Cl
CH2
Cl
Drug
Principal Route
of Administration
mechlorethamine
chlorambucil
melphalan
cyclophosphamide
ifosfamide
intravenous
very short
(1 minute)
oral
oral
1.5 hours
1.5 hours
oral/intravenous
intravenous
7 hours
7 hours
rapid action
potent vessicant
slow rate of
conversion to
carbonium ion
***must be
activated by
liver metabolism
(prodrugs)
Acute
Delayed (Dose-Limiting)
nausea/vomiting
melphalan
mild nausea
cyclophosphamide
nausea/vomiting
ifosfamide
nausea/vomiting
NH2
Pt
Pt
Cl
NH2
O
O
Cl
O
carboplatin
cisplatin
O
NH2
O
Pt
O
O
NH2
oxaliplatin
NH2
cisplatin
Principal Route
of Administration
intravenous
intraperitoneal
Plasma t1/2
20-40 minutes
Characteristics
carboplatin
oxaliplatin
intravenous
intravenous
2-3 hours
Slow reaction
2-3 hours
Slow reaction
cisplatin
carboplatin
oxaliplatin
Acute
severe nausea/vomiting,
anaphylactic reactions
moderate nausea/
vomiting
nausea/vomiting
Delayed (Dose-Limiting)
***nephrotoxicity, ototoxicity,
peripheral neuropathy,
bone marrow suppression
metabolic disorders:
Uremia, ketoacidosis,
hypoxia
chemoreceptor
trigger zone
(area postrema)
anticipitory emesis:
elicited by chemotherapy
(before administration)
vomiting center
motion sickness
inner ear disorders
peripheral receptors
(vagal and splanchnic nerves)
vestibular
center
intestinal injury
toxins
chemotherapy (late)
radiation therapy
mechanism of action
5-HT3 receptor
blockade
Treatment of Chemotherapy-Induced
Bone Marrow Dysfunction
Transfusion of blood components
red blood cells
platelets
granulocytes (rare- cells dont live long)
Hematopoietic cytokines
erythropoietin
G-CSF (filgrastim)
GM-CSF (sargramostim)
chemotherapy
exogenous
chemotherapy
carcinogens
other toxins/irritants
endogenous
metabolism
inflammation
cell signaling
many enzymes
cytochrome P450's
oxidants
electrophiles
inactivated
detoxification
(GSTP1, GSTs, GPx, etc.)
cell death
repair
proliferation
transformation
mutation
genome
damage
0%
chemotherapy alone
RT + MOPP (alkylators)
RT + other alkylators